SomnoMed Ltd (ASX:SOM) Stock Price, Trades & News

SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.

Financial Strength

6/10

Name	Current	Vs Industry
Cash-To-Debt	2.73
Equity-to-Asset	0.63
Debt-to-Equity	0.13
Debt-to-EBITDA	1.17
Interest Coverage	6.99
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.25	Distress Grey Safe
Beneish M-Score	-2.54	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

5/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-8.4
	3-Year EBITDA Growth Rate	68.7
	3-Year EPS without NRI Growth Rate	27.5
	3-Year Book Growth Rate	-5.8
	Future 3-5Y Total Revenue Growth Rate Estimate	9.44

Momentum Rank

8/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	15.72
	9-Day RSI	27.19
	14-Day RSI	33.44
	3-1 Month Momentum %	1.69
	6-1 Month Momentum %	-22.08
	12-1 Month Momentum %	-7.69

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.76
	Quick Ratio	1.46
	Cash Ratio	0.73
	Days Inventory	55.57
	Days Sales Outstanding	46.77
	Days Payable	98.57

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-25.9
	Shareholder Yield %	-0.85

Profitability Rank

3/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	59.81
	Operating Margin %	0.91
	Net Margin %	-2.16
	EBITDA Margin %	4.77
	FCF Margin %	1.58
	OCF Margin %	6.63
	ROE %	-5.34
	ROA %	-3.25
	ROIC %	2.44
	3-Year ROIIC %	317.28
	ROC (Joel Greenblatt) %	-0.05
	ROCE %	-0.01
	Years of Profitability over Past 10-Year	1
	Moat Score	4
	Tariff Resilience Score	6

GF Value Rank

5/10

	Name	Current	Vs Industry		Vs History
	Forward PE Ratio	17.93
	PS Ratio	0.91
	PB Ratio	2.21
	Price-to-Tangible-Book	3.88
	Price-to-Free-Cash-Flow	63.13
	Price-to-Operating-Cash-Flow	14.02
	EV-to-EBIT	-14174.57
	EV-to-EBITDA	17.54
	EV-to-Revenue	0.83
	EV-to-Forward-Revenue	0.8
	EV-to-FCF	56.57
	Price-to-GF-Value	1.12
	Price-to-Median-PS-Value	0.46
	Price-to-Net-Current-Asset-Value	8.42
	Earnings Yield (Greenblatt) %	-0.01
	FCF Yield %	1.7
	Forward Rate of Return (Yacktman) %	7.71

GF Value™: A$0.45

ASX:SOM

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with SOM. Try a 7-Day Free Trial to check it out.

SomnoMed Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

SomnoMed Ltd Stock Events

Financials Calendars

	Event	Date	Price (A$)
	0.05:1 Stock Split	2009-11-27	0.62 (-3.92%)

Show

Entries

Press Release

	Subject	Date
	KILL SomnoMed® Increases Investment in Managed Care Infrastructure	2025-11-21
	SomnoMed® Increases Investment in Managed Care Infrastructure	2025-11-20
	SomnoMed's North America Q1 revenue growth leads the way	2022-10-28
	SomnoMed posts record Q4 and delivers on FY22 revenue guidance	2022-07-26

10/Page

Articles on SomnoMed Ltd

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.